The future of immunotherapyy
At Montani Bio we believe in the potential of mRNA
Popularized by the COVID-19 pandemic, mRNA vaccine technology has been in development for nearly a century by generations of scientists who see its potential for transforming human health. Today, Montani Bio is working hard to continue developing the mRNA platform so its potential applications may be fully realized in cancer therapy, personalized medicine, and more.
Our Candidate Technologies
Genetic Adjuvants
Autogene Therapies
Autogene Therapies
By exploiting the expression of integral cytokines and chemokines in desirable inflammatory pathways, our genetic adjuvant platform can harness the innate power of the immune system to activate favorable responses to vaccines and immunotherapies. In preclinical studies, our candidate genetic adjuvants have been proven to suppress tumor gr
By exploiting the expression of integral cytokines and chemokines in desirable inflammatory pathways, our genetic adjuvant platform can harness the innate power of the immune system to activate favorable responses to vaccines and immunotherapies. In preclinical studies, our candidate genetic adjuvants have been proven to suppress tumor growth in immunotherapy-resistant melanoma (VDC-MB-0001, 0002) and increase antibody response levels to antigen (VDC-MB-0002).
Autogene Therapies
Autogene Therapies
Autogene Therapies
Personalized therapeutics are more achievable than ever with the mRNA platform which simplifies drug design and production. Montani Bio's collaboration with a world class neoantigen prediction algorithm enables our exciting cancer autogene therapy platform which delivers potent tumor-specific neoantigens to the host to drive durable anti-
Personalized therapeutics are more achievable than ever with the mRNA platform which simplifies drug design and production. Montani Bio's collaboration with a world class neoantigen prediction algorithm enables our exciting cancer autogene therapy platform which delivers potent tumor-specific neoantigens to the host to drive durable anti-tumor immunity. This platform is currently being investigated for use in melanoma and breast cancer.
Targeted Antigens
Autogene Therapies
Targeted Antigens
Canonical expression of mRNA-encoded payloads in vivo fail to harness the full potential of mRNA-LNP interactions in the host. At Montani Bio we are iteratively exploring how novel expression signals added in silico could improve the presentation and processing of these proteins in the host.